Form 4: Myriad Genetics Executive Mark Verratti Reports Stock Transaction

Mark Verratti, Chief Commercial Officer of Myriad Genetics, reports the withholding of 1,076 common stock shares to cover tax obligations related to vesting restricted stock units.

Summary

• On April 14, 2024, Mark Verratti, the Chief Commercial Officer of Myriad Genetics Inc., reported a transaction involving the company's common stock.
• The transaction involved the withholding of 1,076 shares of common stock to satisfy tax withholding obligations.
• These obligations arose in connection with the vesting of restricted stock units granted to Mr. Verratti.
• The shares were withheld by the company at a price of $19.55 per share, based on the closing price of Myriad common stock on April 12, 2024.
• Following the transaction, Mr. Verratti beneficially owns 298,715 shares of Myriad Genetics common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a routine stock transaction. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency to investors regarding insider transactions.

Stakeholder Impact

• The transaction has a minimal direct impact on stakeholders, as it is a routine tax withholding.

Key Dates